VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis

R. Wild; Y. Yokoyama; R. P.M. Dings; Sundaram Ramakrishnan

doi:10.1023/B:BREA.0000025407.02896.ec

VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis

R. Wild, Y. Yokoyama, R. P.M. Dings, Sundaram Ramakrishnan

Pharmacology

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Previous experiments have shown that a vascular endothelial growth factor (VEGF)-DT385 toxin conjugate inhibits endothelial cell proliferation, angiogenesis and solid tumor growth in a xenotransplant model system. Here, we report that VEGF-DT385 toxin conjugate effectively inhibits spontaneous tumorigenesis. The C3(1)/SV40 TAg transgenic mouse model of mammary gland carcinogenesis was used to determine the effectiveness of VEGF-DT385 toxin conjugate in delaying the onset of disease and the development of solid tumors. Animals were treated daily with conjugate for a period of 7 days. Therapy was initiated at week 14 of development before any visible adenocarcinomas were evident. Treatment of mice with VEGF-DT385 toxin conjugate significantly delayed the onset of tumorigenesis and inhibited solid tumor growth by more than 92%. Furthermore, conjugate treated animals showed less than twice the number of tumor nodules when compared to control mice. Finally, this vascular targeting agent significantly increased survival time of animals by 5 weeks. VEGF-DT385 toxin conjugate resulted in temporary weight loss and no long-lasting toxicity was seen. More importantly, using this established tumor model, VEGF-DT385 toxin conjugate appeared to be as effective as a similar treatment schedule with recombinant human endostatin. Our results suggest that VEGF-DT385 toxin conjugate is a potent inhibitor of mammary adenocarcinoma growth and might be useful in breast cancer therapy.

Original language	English (US)
Pages (from-to)	161-171
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	85
Issue number	2
DOIs	https://doi.org/10.1023/B:BREA.0000025407.02896.ec
State	Published - May 2004

Bibliographical note

Funding Information:
This work was supported in part by, grants from NIH CA 71803, DAMD 17-99-1-9564 from USARMY, Sparboe and Women’s Health Fund Endowment (to S.R.) and a doctoral dissertation fellowship from the University of Minnesota Graduate School (to R.W.). We thank Dr Jeffrey E. Green (National Cancer Institute, NIH, Bethesda, MD) for providing the C3(1)/SV40 TAg transgenic mice. In addition, we thank Dr Roland Gunther (Division of Comparative Medicine, Department of Research Animal Resources, University of Minnesota, Minneapolis, MN) for histologic examination of tissues.

Keywords

Angiogenesis
Endostatin
Mammary carcinoma
Tumorigenesis
VEGF-DT385 toxin
Vascular targeting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1023/B:BREA.0000025407.02896.ec

OpenUrl availability

Full text

Cite this

@article{a2701508fb85463ba09d6b617021396b,

title = "VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis",

abstract = "Previous experiments have shown that a vascular endothelial growth factor (VEGF)-DT385 toxin conjugate inhibits endothelial cell proliferation, angiogenesis and solid tumor growth in a xenotransplant model system. Here, we report that VEGF-DT385 toxin conjugate effectively inhibits spontaneous tumorigenesis. The C3(1)/SV40 TAg transgenic mouse model of mammary gland carcinogenesis was used to determine the effectiveness of VEGF-DT385 toxin conjugate in delaying the onset of disease and the development of solid tumors. Animals were treated daily with conjugate for a period of 7 days. Therapy was initiated at week 14 of development before any visible adenocarcinomas were evident. Treatment of mice with VEGF-DT385 toxin conjugate significantly delayed the onset of tumorigenesis and inhibited solid tumor growth by more than 92%. Furthermore, conjugate treated animals showed less than twice the number of tumor nodules when compared to control mice. Finally, this vascular targeting agent significantly increased survival time of animals by 5 weeks. VEGF-DT385 toxin conjugate resulted in temporary weight loss and no long-lasting toxicity was seen. More importantly, using this established tumor model, VEGF-DT385 toxin conjugate appeared to be as effective as a similar treatment schedule with recombinant human endostatin. Our results suggest that VEGF-DT385 toxin conjugate is a potent inhibitor of mammary adenocarcinoma growth and might be useful in breast cancer therapy.",

keywords = "Angiogenesis, Endostatin, Mammary carcinoma, Tumorigenesis, VEGF-DT385 toxin, Vascular targeting",

author = "R. Wild and Y. Yokoyama and Dings, {R. P.M.} and Sundaram Ramakrishnan",

note = "Funding Information: This work was supported in part by, grants from NIH CA 71803, DAMD 17-99-1-9564 from USARMY, Sparboe and Women{\textquoteright}s Health Fund Endowment (to S.R.) and a doctoral dissertation fellowship from the University of Minnesota Graduate School (to R.W.). We thank Dr Jeffrey E. Green (National Cancer Institute, NIH, Bethesda, MD) for providing the C3(1)/SV40 TAg transgenic mice. In addition, we thank Dr Roland Gunther (Division of Comparative Medicine, Department of Research Animal Resources, University of Minnesota, Minneapolis, MN) for histologic examination of tissues.",

year = "2004",

month = may,

doi = "10.1023/B:BREA.0000025407.02896.ec",

language = "English (US)",

volume = "85",

pages = "161--171",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis

AU - Wild, R.

AU - Yokoyama, Y.

AU - Dings, R. P.M.

AU - Ramakrishnan, Sundaram

N1 - Funding Information: This work was supported in part by, grants from NIH CA 71803, DAMD 17-99-1-9564 from USARMY, Sparboe and Women’s Health Fund Endowment (to S.R.) and a doctoral dissertation fellowship from the University of Minnesota Graduate School (to R.W.). We thank Dr Jeffrey E. Green (National Cancer Institute, NIH, Bethesda, MD) for providing the C3(1)/SV40 TAg transgenic mice. In addition, we thank Dr Roland Gunther (Division of Comparative Medicine, Department of Research Animal Resources, University of Minnesota, Minneapolis, MN) for histologic examination of tissues.

PY - 2004/5

Y1 - 2004/5

N2 - Previous experiments have shown that a vascular endothelial growth factor (VEGF)-DT385 toxin conjugate inhibits endothelial cell proliferation, angiogenesis and solid tumor growth in a xenotransplant model system. Here, we report that VEGF-DT385 toxin conjugate effectively inhibits spontaneous tumorigenesis. The C3(1)/SV40 TAg transgenic mouse model of mammary gland carcinogenesis was used to determine the effectiveness of VEGF-DT385 toxin conjugate in delaying the onset of disease and the development of solid tumors. Animals were treated daily with conjugate for a period of 7 days. Therapy was initiated at week 14 of development before any visible adenocarcinomas were evident. Treatment of mice with VEGF-DT385 toxin conjugate significantly delayed the onset of tumorigenesis and inhibited solid tumor growth by more than 92%. Furthermore, conjugate treated animals showed less than twice the number of tumor nodules when compared to control mice. Finally, this vascular targeting agent significantly increased survival time of animals by 5 weeks. VEGF-DT385 toxin conjugate resulted in temporary weight loss and no long-lasting toxicity was seen. More importantly, using this established tumor model, VEGF-DT385 toxin conjugate appeared to be as effective as a similar treatment schedule with recombinant human endostatin. Our results suggest that VEGF-DT385 toxin conjugate is a potent inhibitor of mammary adenocarcinoma growth and might be useful in breast cancer therapy.

AB - Previous experiments have shown that a vascular endothelial growth factor (VEGF)-DT385 toxin conjugate inhibits endothelial cell proliferation, angiogenesis and solid tumor growth in a xenotransplant model system. Here, we report that VEGF-DT385 toxin conjugate effectively inhibits spontaneous tumorigenesis. The C3(1)/SV40 TAg transgenic mouse model of mammary gland carcinogenesis was used to determine the effectiveness of VEGF-DT385 toxin conjugate in delaying the onset of disease and the development of solid tumors. Animals were treated daily with conjugate for a period of 7 days. Therapy was initiated at week 14 of development before any visible adenocarcinomas were evident. Treatment of mice with VEGF-DT385 toxin conjugate significantly delayed the onset of tumorigenesis and inhibited solid tumor growth by more than 92%. Furthermore, conjugate treated animals showed less than twice the number of tumor nodules when compared to control mice. Finally, this vascular targeting agent significantly increased survival time of animals by 5 weeks. VEGF-DT385 toxin conjugate resulted in temporary weight loss and no long-lasting toxicity was seen. More importantly, using this established tumor model, VEGF-DT385 toxin conjugate appeared to be as effective as a similar treatment schedule with recombinant human endostatin. Our results suggest that VEGF-DT385 toxin conjugate is a potent inhibitor of mammary adenocarcinoma growth and might be useful in breast cancer therapy.

KW - Angiogenesis

KW - Endostatin

KW - Mammary carcinoma

KW - Tumorigenesis

KW - VEGF-DT385 toxin

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=3342953026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342953026&partnerID=8YFLogxK

U2 - 10.1023/B:BREA.0000025407.02896.ec

DO - 10.1023/B:BREA.0000025407.02896.ec

M3 - Article

C2 - 15111774

AN - SCOPUS:3342953026

SN - 0167-6806

VL - 85

SP - 161

EP - 171

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this